Drug Profile
Seralutinib - Gilead Sciences/Gossamer Bio
Alternative Names: GB-002; PK-10571Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator YM BioSciences
- Developer Gossamer Bio
- Class Amides; Antihypertensives; Pyrazines; Pyridines; Small molecules
- Mechanism of Action Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pulmonary arterial hypertension
Most Recent Events
- 05 Mar 2024 PMDA of Japan approves clinical trial application for phase-III PROSERA trial in Pulmonary arterial hypertension (Inhalation) prior to March 2024
- 27 Feb 2024 Gossamer Bio plans the phase III PROSERA-EXT trial for Pulmonary arterial hypertension in USA in June 2024 (Inhalation, capsule) (NCT06274801) (EudraCT 2023-5063-3475)
- 31 Dec 2023 Gossamer Bio has patents pending for combination treatment with seralutinib